PM
ADMS

Prosight Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Prosight Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-12,000
Closed -$407K – 39
2017
Q4 		$407K Buy
+12,000
New +$335K 0.3% 29

Other funds holding ADMS

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BWCA
Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Prosight Management's ADMS Position: Q1 2018 in Review

Prosight Management sold out of Adamas Pharmaceuticals (ADMS) in Q1 2018, closing a stake of 12,000 shares — an estimated $407K sold.

Prosight Management first reported a position in ADMS in Q4 2017 and held it in 1 quarter. The position peaked at $407K in Q4 2017. 118 funds tracked by Wall St. Rank hold ADMS as of Q1 2018.

  • Prosight Management reported no remaining Adamas Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Prosight Management sold 12,000 Adamas Pharmaceuticals shares in Q1 2018, an estimated $407K.
  • Prosight Management first reported a position in Adamas Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Prosight Management's Adamas Pharmaceuticals position peaked at $407K in Q4 2017.
  • 118 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2018.

Based on Prosight Management's 13F filing for Q1 2018, filed 14 May 2018.